Todd Alekshun, MD
Hematology & Oncology · Hartford, CTNPI 1558495689
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,700 of the $22,300 with a category attached, or 74.9%. AstraZeneca accounts for 80.3% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2019 at $17,216 and has fallen 99.0% since, to $174 in 2024.
Across 297 payments — averaging $75.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Johnson & Johnson$535
- Genentech USA, Inc.$432
- Novartis$425
- Pfizer$392
- Merck$309
- plus $2K from 37 others
Across 8 payments — averaging $11,636 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$93K
What the payments were for
- Speaking & faculty fees$16,70075%
- Travel & lodging$8184%
- Food & beverage$4,44220%
- Education$3402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,300 in reported general payments places this provider in the 85th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 47 | $823,202 |
| Lenalidomide | 63 | $721,961 |
| PomalystPomalidomide | 28 | $700,320 |
| Abiraterone Acetate | 118 | $474,940 |
| RevlimidLenalidomide | 24 | $421,029 |
| JakafiRuxolitinib Phosphate | 23 | $405,228 |
| VenclextaVenetoclax | 28 | $385,023 |
| AlecensaAlectinib Hcl | 12 | $367,516 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $308,202 |
| NinlaroIxazomib Citrate | 21 | $273,832 |
| BesremiRopeginterferon Alfa-2b-Njft | 12 | $196,647 |
| CalquenceAcalabrutinib Maleate | 12 | $163,099 |
| TazverikTazemetostat Hydrobromide | 12 | $119,939 |
| XareltoRivaroxaban | 86 | $99,504 |
| EliquisApixaban | 107 | $96,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $17,898 | $986,30159 claims |
| Bristol Myers SquibbRevlimid | $153 | $421,02924 claims |
| Incyte CorporationJakafi | $52 | $405,22823 claims |
| AbbVieVenclexta | $45 | $385,02328 claims |
| Genentech USA, Inc.Alecensa | $432 | $367,51612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $66 | $273,83221 claims |
| Ipsen Biopharmaceuticals, IncTazverik | $49 | $119,93912 claims |
| Johnson & JohnsonXarelto | $535 | $99,50486 claims |
| PfizerEliquis | $392 | $96,537107 claims |
| Lilly USA, LLCOlanzapine | $76 | $16635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Hartford
- Madhavi GorusuHartford$207K
- Adam BoruchovHartford$55K
- Shabnam RehmanHartford$25K
- Yelena PristyazhnyukHartford$9K
- Kin Wai HungHartford$7K
- Stephen FirsheinHartford$7K
- Paul DekkerHartford$6K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.